Chairman & Chief Executive Officer
Josh Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Prior to forming Aytu BioScience, Josh was the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE) and led the Luoxis Diagnostics subsidiary. Luoxis was merged into Aytu in April 2015 following Luoxis’ development of the technology behind the company’s MiOXSYS in vitro diagnostic platform. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals.Read more...
Josh began as Arbor’s second employee and oversaw the commercialization of the company’s first product, scaling the commercial organization to over 150 people across sales, marketing, payer markets, distribution, commercial operations, and national accounts. In less than four years, Arbor grew from a company without any product revenues to a company with net sales of over $120 million. Prior to joining Arbor, he was the Director of Marketing at LipoScience (NASDAQ: LPDX), a cardiovascular in vitro diagnostic company. Josh also served in sales management at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices. Josh started his career at Glaxo Wellcome (now GlaxoSmithKline plc), holding positions in both sales and marketing. He has a Master of Business Administration from Wake Forest University and Bachelor of Science in Management from North Carolina State University.
Chair, Compensation Committee
Gary Cantrell has thirty years’ experience in the life sciences industry ranging from clinical experience as a respiratory therapist to his current executive-level consulting role with Mayne Pharma (ASX: MYX), as business development executive focused on acquiring branded prescription assets for Mayne Pharma’s U.S. specialty brands division.Read more...
Prior to forming his professional consultancy, Gary served as CEO of Yasoo Health Inc., a global specialty nutritional company from 2007 to 2015, highlighted by the sale of its majority asset, AquADEKs, to Actavis in March 2015. He was also president of the Catevo Group, a North Carolina-based healthcare consulting firm, and Executive Vice President, Sales and Marketing at TEAMM Pharmaceuticals, an Accentia Biopharmaceuticals company. Mr. Cantrell started his pharmaceutical career at GSK, where he held multiple senior management positions in sales, marketing and business development over a period of 22 years. He has served as an advisor or board member of several emerging life science companies including his previous role as a board member at Flexible Stenting Solutions, Inc., which was sold to Cordis, while a division of Johnson & Johnson in March 2013. Mr. Cantrell is a graduate of Wichita State University.
Chair, Nominating & Governance Committee
Carl Dockery is a financial executive with many years of experience in the insurance and reinsurance industry and more recently in 2006 as the founder of a registered investment advisory firm, Alpha Advisors, LLC. Carl’s 20-year career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as Vice President of Gulf Insurance Co. Ltd. of Grand Cayman.Read more...
Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd’s and the London Underwriting Centre brokering various types of reinsurance placements. Carl is currently a member of the Board of Directors of CytoDyn, Inc., a publicly traded biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection and is an active investor in various healthcare companies through Alpha Ventures, the venture capital affiliate of Alpha Advisors. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities.
John Donofrio, Jr.
Chair, Audit Committee
John Donofrio has spent over 24 years in the pharmaceutical industry, and he has a broad range of experience in consolidated financial reporting, international accounting and internal controls, budget and forecast planning, mergers and acquisitions, business development and other strategic and financial areas.Read more...
Mr. Donofrio has served as the Chief Financial Officer and Head of North American Business Development for Merz North America, or Merz, since August 2013. Mr. Donofrio has been instrumental in Merz North America’s growth; sales and profit have more than doubled since he joined the company. Previously, he served as interim CFO and Vice President of Stiefel Global Finance, U.S. Specialty Business and Puerto Rico, for Stiefel, a GlaxoSmithKline plc. company (GSK). He was also the senior finance partner for the U.S. specialty business units of GSK and previously held positions of increasing responsibility at GlaxoSmithKline within finance and accounting. Mr. Donofrio holds a degree in accounting from North Carolina State University.
Michael Macaluso is the Chairman and Chief Executive Officer of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE). Mike founded Ampio Pharmaceuticals in 2010 through a merger with DMI Life Sciences, and he has been Chairman of the Board of Directors since the company’s inception.Read more...
Mike was appointed Ampio’s Chief Executive Officer in January 2012 and has advanced the company’s preclinical development assets into late-stage clinical trials whereby Ampio is now engaged in the second US pivotal study with its lead therapeutic agent Ampion, a novel biologic being studied for the treatment of osteoarthritis of the knee. Prior to founding Ampio Mike was President, Chief Executive Officer, and a member of the Board of Directors of Isolagen, Inc. (AMEX: ILE), a biotechnology company. From October 1998 until June 2001, Mike was the owner of Page International Communications, a global manufacturing business. Mike was also a founder and principal of International Printing and Publishing, a position Mike held from 1989 until 1997, when he sold that business to a private equity firm. Mike is a graduate of Canisius College.